Positive Updated Ph 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma Announced July 28, 2026
Last Patient, Last Visit in LAM561 Ph 2b/3 Trial for Newly Diagnosed GBM Patients Announced July 28, 2026
Positive Updated Ph 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma Announced July 21, 2026
Encouraging Preliminary Data from Ongoing Ph 2 Study of BPM31510 in Newly Diagnosed GBM Reported July 21, 2026
FDA Provides Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition July 21, 2026
FORE Biotherapeutics Announces Closing of Upsized $67.4 Million Series D-2 Extension Financing and Highlights Recent Plixorafenib Achievements July 15, 2026
Publication in The JCO Demonstrating DeltEx DRI Doubles PFS in Newly Diagnosed Glioblastoma July 15, 2026
Updated Survival Data Presented from Ph 3 Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses July 15, 2026
Orphan Drug Designation Request submitted to the FDA for GDT Cell Therapy Targeting Glioblastoma July 15, 2026
Siren Biotechnology Awarded $8M in Non-Dilutive Grant Funding from CIRM to Support Clinical Development of SRN-101 in High-Grade Glioma June 30, 2026
FAILED TRIAL: Ph 3 TRIDENT trial of TTFields did not meet primary endpoint of significant OS increase in GBM patients when used early June 23, 2026
UAE IND Approval obtained for NEO212 Following Successful Ph 1 Completion, Advancing Toward Global Ph 2 Development June 23, 2026
FDA Clearance Received to Complete Enrollment in REGAIN Recurrent GBM Trial and Addition of Two US Clinical Sites June 17, 2026
First patient dosed in clinical trial of EDV™ (EnGeneIC Dream Vector) therapy in patients with recurrent GBM May 12, 2026
Interim Results Announced of US Alpha DaRT® REGAIN Trial, with 100% Local Disease Control, 67% CRR, and Favorable Safety Profile May 12, 2026
Taletrectinib (IBTROZI®) Added as Recommended Option to NCCN Guidelines for CNS Cancers April 28, 2026
Ojemda® approved in the EU in R/R pediatric low-grade glioma regardless of BRAF alteration April 28, 2026
FDA granted Breakthrough Therapy Designation (BTD) to plixorafenib for the treatment of adult patients with BRAF V600E-mutated high-grade glioma (HGG) April 7, 2026
FDA Fast Track Designation for SRN-101 for the Treatment of Recurrent High-Grade Glioma March 24, 2026
